Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Adenoma, Islet Cell 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × montanide ISA 51 × 1 year × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡